Christine Y Lu

Célpontok

• PD-L1 1
• SGLT2 1
• TNF 1

A kitöltött címkéket a kutató adta meg; a többi a publikációkból jön (a munkák száma).

Most

Vizsgálatok, publikációk és pályázatok 2024. nov. óta.

• Publikáció

  The cost of delay: foregone public expenditure savings from delayed adalimumab biosimilar listing in Australia's Pharmaceutical Benefits Scheme.

  Expert opinion on biological therapy, 2026. okt.

• Publikáció

  Cost-effectiveness of first-line pembrolizumab monotherapy in PD-L1-high metastatic non-small cell lung cancer in Australia: evidence from trials and real-world practice.

  International journal of clinical pharmacy, 2026. júl.

• Publikáció

  Cardiovascular safety of romosozumab versus denosumab for osteoporosis treatment: a multinational real-world data analysis.

  Therapeutic advances in musculoskeletal disease, 2026. júl.

• Publikáció

  Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.

  Targeted oncology, 2026. máj.

• Publikáció

  Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

  Clinical pharmacology and therapeutics, 2026. máj.

• Publikáció

  Cost-effectiveness of pembrolizumab plus chemotherapy for metastatic non-small cell lung cancer: a head-to-head trial vs. real-world comparison.

  Journal of medical economics, 2026. ápr.

• Publikáció

  Downstream Treatment Burden and Health-Care Utilization Following Initiation of GLP-1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes.

  Diabetes, obesity & metabolism, 2026. márc.

• Publikáció

  Real-World Safety of Immune Checkpoint Inhibitors in Small Cell Lung Cancer: A Systematic Review of Comparative Cohort Studies.

  Current oncology reports, 2026. márc.

• Publikáció

  Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study.

  Lung cancer (Amsterdam, Netherlands), 2026. febr.

• Publikáció

  Real-World Outcomes of Pembrolizumab Monotherapy in Metastatic Non-Small Cell Lung Cancer by Age and Sex: A National Population-Based Study in Australia.

  Clinical pharmacology and therapeutics, 2026. jan.

• Publikáció

  Prasugrel Outperforms Ticagrelor in Acute Coronary Syndrome: A Real-World Analysis.

  Cardiovascular therapeutics, 2026. jan.

• Publikáció

  Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study.

  BMC infectious diseases, 2025. dec.

• Publikáció

  The health and economic burden of lung cancer in Australia: A dynamic model of quality of life and productivity loss.

  Journal of cancer policy, 2025. dec.

• Publikáció

  Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis.

  Ageing research reviews, 2025. dec.

• Publikáció

  Workplace productivity losses due to cancer: findings from an Australian longitudinal population survey (2009-2021).

  Expert review of pharmacoeconomics & outcomes research, 2025. nov.

Intézmények

• The University of Sydney
• Florey Institute of Neuroscience and Mental Health
• Austin Health
• The University of Melbourne
• Royal North Shore Hospital

Társszerzők

Ki köt össze minket

Add meg egy másik kutató profiljának linkjét vagy azonosítóját: megmutatjuk, ki publikált mindkettőtökkel.